Clinical Applications of Argatroban in the Treatment of Acute Ischemic Stroke

doi:10.3969/j.issn.1673-5765.2017.09.024

Abstract

Abstract:

Argatroban is a direct thrombin inhibitor with the advantages of rapid onset, short duration of effect, less tendency of bleeding and no immunogenicity, which can effectively prevent thrombosis and secondary microthrombosis. Several studies home and abroad had proved that argatroban could effectively improve the neurologic symptoms and daily activity ability of patients with acute ischemic stroke, and it also had therapeutic effect in patients with acute atherosclerotic stroke or cardioembolic stroke. Compared with aspirin, ozagrel and and other antiplatelet drugs or heparin, argatroban has higher safety. Due to the different mechanism of action, the combination therapy with aspirin, clopidogrel and other antiplatelet drug or recombinant tissue plasminogen activator (rt-PA) may show the possibility of synergistic effect. This paper focuses on the clinical application of argatroban in the treatment of acute ischemic stroke.

Key words: Argatroban; Acute ischemic stroke; Anticoagulation

摘要：

阿加曲班是一种直接凝血酶抑制剂，具有起效较快、作用时间短、出血倾向小、无免疫源性等优点，能够有效阻止血栓进展，防止继发微血栓形成。国内外多项研究证实，阿加曲班能有效改善急性缺血性卒中患者的神经系统症状和日常活动能力，且对急性动脉粥样硬化性卒中和心源性卒中均有治疗作用，此外，阿加曲班与阿司匹林、奥扎格雷等抗血小板药物以及肝素相比疗效更显著，具有较高的安全性，同时由于作用机制不同，阿加曲班与阿司匹林、氯吡格雷等抗血小板药物、重组组织型纤溶酶原激活物（recombinant tissue plasminogen activator，rt-PA）联合治疗可能发挥协同作用。本文就阿加曲班在急性缺血性卒中的临床应用做一系统性综述。

关键词: 阿加曲班; 急性缺血性卒中; 抗凝

QUAN Ke-Hua, MA Lin, PAN Yue-Song, YANG Xiao-Meng, CHEN Wei-Qi, WANG Yi-Long, CHEN Hui-Sheng. Clinical Applications of Argatroban in the Treatment of Acute Ischemic Stroke[J]. Chinese Journal of Stroke, 2017, 12(09): 869-873.

全柯桦，马琳，潘岳松，杨晓萌，陈玮琪，王伊龙，陈会生. 阿加曲班治疗急性缺血性卒中的临床应用[J]. 中国卒中杂志, 2017, 12(09): 869-873.

References

1 陈长青，赵伟苗，贺同页，等. 阿加曲班注射液治疗急

性脑梗死患者的有效性和安全性观察[J]. 现代药物

与临床，2013，28（5）：729-751.

2 KOBAYASHI S，TAZAKI Y. Effect of the thrombin

inhibitor Argatroban in acute cerebral thrombosis[J].

Semin Thromb Hemost，1997，23（6）：531-534.

3 HIDENOBU I. Development of argatroban as an

anticoagulant and antithrombin agentin Japan[J].

Pathophysiol Haemost Thromb，2002，32（3）：23-

28.

4 许俊堂. 阿加曲班临床应用的进展[J]. 血栓与止血学，

2007，13（4）：180-182.

5 JUNG S，SEUNG S，EUN J，et al. Treatment for

patients with acute ischemic stroke presenting

beyond six hours of ischemic symptom onset：

effectiveness of intravenous direct thrombin inhibitor，

argatroban[J]. J Korean Neurosurg Soc，2010，47（7）：

258-264.

6 MARIAN P，LAMONTE，MARSHALL L，et al.

Argatroban anticoagulation in patients with acute

ischemic stroke（ARGIS-1）a randomized，placebocontrolled

safety study[J]. Stroke，2004，35（7）：

1677-1682.

7 赵秀欣，张微微，魏亚洲. 阿加曲班治疗急性缺血

性脑卒中的临床研究[J]. 中华老年心脑血管病杂志，

2010，12（9）：820-822.

8 TOMOKI W，HIDEO Y，HIROMASA H，et al.

Outcomes of argatroban treatment in patients with

atherothrombotic stroke observational nationwide

study in Japan[J]. Stroke，2016，47（2）：471-476.

9 NAOHISA H. Efficacy of anti-coagulant treatment

with argatroban on cardioembolic stroke[J]. J Neurol，

2007，254（5）：605-612.

10 李冬梅. 阿加曲班治疗急性缺血性脑卒中的疗效观

察及其不良反应[J]. 血栓与止血学，2015，21（4）：

209-211.

11 樊云峰. 小剂量阿加曲班对比阿司匹林治疗急性脑

梗死的临床观察[J]. 中国药房，2015，26（21）：2933-

2935.

12 朱晓冬，王景，华程焱. 阿加曲班治疗急性脑梗死的

有效性和安全性研究[J]. 天津医药，2006，34（6）：

376-378.

13 孙茜，常淑美，魏冬梅. 阿加曲班与奥扎格雷对急性

缺血性脑卒中的临床疗效比较[J]. 中国医院药学杂

志，2014，34（14）：1200-1202.

14 刘梦婵，李凤鹏，韩雅玲，等. 阿加曲班对比阿司匹

林联合氯吡格雷治疗急性缺血性卒中的初步随机、

开放研究[J]. 解放军医学杂志，2015，40（6）：435-

439.

15 陈晓东，任旭东，魏俊妮. 阿加曲班注射液与阿司匹

林联合治疗短暂性脑卒中的疗效评价[J]. 中国药物

与临床，2017，3（17）：398-399.

16 李霞，李小媛，潘瑞春. 阿加曲班注射液与阿司匹林

联合治疗短暂性脑卒中的疗效评价[J]. 中西医结合

心血管病电子杂志，2017，5（4）：6-7.

17 黄炎青，陈焱，赵美萍，等. 阿加曲班联合阿司匹林

治疗短暂性脑缺血临床观察[J]. 世界最新医学信息

文摘，2016，16（92）：113.

18 范佳，叶宏伟，温仲民，等. 阿加曲班联合阿司匹林

治疗急性脑梗死疗效的研究[C]. 中国医院药学杂志，

2016，15（8）：97-98.

19 孙慧勤，刘芷含，张青山. 阿加曲班联合硫酸氢氯吡

格雷治疗急性脑梗死疗效及安全性评估[J]. 中国继

续医学教育，2016，8（32）：191-193.

20 牟振弘，李斌，张玉香，等. 阿加曲班联合氯吡格雷

治疗大动脉粥样硬化性脑梗死的临床研究[J]. 现代

药物与临床，2015，30（1）：57-60.

21 陈磊，张婧. 奥扎格雷钠联合阿加曲班治疗短暂性脑

缺血发作的疗效观察[J]. 中国医院药学杂志，2014，5

（9）：749-751.

22 REBECCA M，JENNIFER K，KEN U，et al.

Argatroban tPA stroke study：Study design and

results in the first treated cohort[J]. Arch Neurol，

2006，63（8）：1057-1062.

23 ANDREW D，ANDREI V，PAT L，et al. The

argatroban and tPA stroke study：final results of a

pilot safety study[J]. Stroke，2012，43（3）：770-775.

24 ANDREW D，GARY A，LOREN S，et al.

Randomized，multicenter trial of ARTSS-2

（argatroban with recombinant tissue plasminogen

activator for acute stroke）[J]. Stroke，2017，48（6）：

1608-1616.

[1]	XIANG Wei, XU Luyao, ZHANG Manman, WEI Hongchun, LIANG Zhigang. The Frequency and Influencing Factors of Asymmetrical Prominent Veins Sign on Susceptibility-Weighted Imaging in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1097-1102.
[2]	ZHANG Boyu, GUO Yucheng, CUI Yuxia, LI Yingli, LYU Yumei. Seeking Medical Services Decision-Making Status and Relevant Influencing Factors in Patients with Acute Ischemic Stroke: A Review [J]. Chinese Journal of Stroke, 2022, 17(10): 1127-1132.
[3]	WU Tingting, LIU Yafei, YAN Shixi, WU Yiping, ZHANG Zhongbo, ZAHNG Hanfei, FANG Pinping. Application of “Internet Plus” in Emergency Care of Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1133-1138.
[4]	ZHENG Wei, ZHAI Huazheng, CHEN Mengmeng, WANG Jingye. Efficacy and Safety of Direct Thrombectomy versus Bridging Therapy for Acute Ischemic Stroke: A Meta-Analysis [J]. Chinese Journal of Stroke, 2022, 17(07): 720-729.
[5]	ZHOU Juan, TAN Yunbin, WANG Tiejun, SHI Fuming, YU Ping. Incidence and Influencing Factors of Anxiety and Depression in Caregivers of Patients with Acute Ischemic Stroke during Hospitalization [J]. Chinese Journal of Stroke, 2022, 17(07): 764-768.
[6]	XUAN Guiying, FAN Caili, XUAN Lixia, ZHAO Qianqian, LI Xuemei. Analysis of Reasons for Loss of Follow-up among Acute Ischemic Stroke Patients during the COVID-19 Pandemic [J]. Chinese Journal of Stroke, 2022, 17(06): 648-652.
[7]	ZHANG Dong, LI Zhizhang, MA Ruinan, YUE Yunhua. Correlation between Stress Hyperglycemia Ratio and Clinical Prognosis of Patients with Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(05): 483-490.
[8]	HUANG Yan, FU Xuejun, SHI Huijie, ZOU Liangyu. Correlation between Triglyceride-Glucose Index and Neurological Function Impairment after Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(03): 251-257.
[9]	LIU Zhong, LIU Yuanyuan, XU Shaofeng, GUO Wei, KANG Hai. Correlation Analysis of Systemic Immune-Inflammatory Index with Severity and Prognosis of Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(03): 285-291.
[10]	GUO Songtao, E Bu, LI Zhiqiang, JIANG Hao, XU Yuzhu, SUN Jian, SHI Jianmin, WU Xi, GUO Wei. Advances in the Application of 5G Mobile Stroke Unit [J]. Chinese Journal of Stroke, 2022, 17(02): 113-117.
[11]	HUO Xiaochuan, LI Xiaoqing, MIAO Zhongrong, Expert Committee for Neurointervention Quality Control of National Center for Healthcare Quality Management in Neurological Diseases, Endovascular Treatment Working Committee of National Action for Quality Improvement of Acute Cerebral Infarction Reperfusion Therapy. A Survey of Current Practice in Acute Ischemic Stroke Endovascular Treatment in China in 2020 [J]. Chinese Journal of Stroke, 2022, 17(01): 56-65.
[12]	CHEN Zhengyu, CHEN Guofang, CHEN Tong, MA Dongjiao. Influencing Factors of Leukoaraiosis at Different Brain Regions in Patients with Intravenous Thrombolysis for Acute Ischemic Strok [J]. Chinese Journal of Stroke, 2021, 16(12): 1248-1252.
[13]	LIU Ying, DING Jing, WANG Xin. Advances in Futile Recanalization of Endovascular Thrombectomy for Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2021, 16(10): 1067-1074.
[14]	ZHANG Dan-Feng, QIU-Gang, YU Guo-Shen, XI Zhen-Hua, PAN Wen-Liang, MA Xiao-Dong. Current Status of Anticoagulant Therapy in Acute Ischemic Stroke Patients with Atrial Fibrillation in Jiaxing [J]. Chinese Journal of Stroke, 2021, 16(08): 763-769.
[15]	LIU Ting, LIAO Juan, LIU Li, ZHAO Li-Bo, LIU Shu-Dong, XU Lu, ZHOU Ting, YANG De-Yu. Analysis on the Predictive Value of Modified Cincinnati Prehospital Stroke Severity Scale for Acute Large Vessel Occlusion in Anterior Circulation [J]. Chinese Journal of Stroke, 2021, 16(07): 687-693.